SMTI
Sanara Medtech Inc
35.10$
-0.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 25.7% | 25.7% | 24.2% | 28.4% | 36.0% | 37.8% | 38.2% | 34.1% | 43.9% | 46.0% | 45.0% | 46.6% | |
| 8.3% | 7.0% | 4.0% | 8.4% | 18.4% | 18.0% | 21.5% | 17.2% | 21.0% | 22.7% | 19.6% | 22.3% | |
| 8.3% | 7.0% | 4.0% | 8.4% | 18.4% | 18.0% | 21.5% | 17.2% | 21.0% | 22.7% | 19.6% | 22.3% | |
| 9.9% | 11.6% | 13.0% | 14.5% | 13.8% | 15.4% | 12.4% | 12.1% | 17.0% | 16.4% | 19.7% | 18.2% | |
| 6.7% | 6.4% | 6.0% | 4.9% | 3.4% | 3.1% | 3.3% | 3.6% | 4.8% | 5.4% | 4.5% | 5.0% | |
| 4.8% | 4.9% | 5.1% | 4.9% | 4.1% | 4.1% | 3.7% | 3.6% | 5.1% | 4.9% | 5.2% | 5.2% | |
| 60.9% | 60.8% | 62.0% | 58.6% | 47.5% | 46.5% | 43.6% | 41.5% | 29.7% | 25.6% | 25.8% | 25.0% | |
| 41.6% | 39.6% | 39.3% | 43.6% | 55.4% | 55.8% | 62.0% | 64.2% | 91.4% | 91.9% | 89.9% | 88.5% | |
| 17.5% | 18.6% | 18.0% | 15.8% | 16.2% | 17.4% | 13.8% | 15.1% | 24.4% | 25.5% | 19.8% | 18.1% | |
| 0.7% | 1.3% | 1.8% | 0.5% | 0.5% | 0.4% | 0.2% | 0.2% | 0.5% | 0.5% | 0.5% | 0.6% | |
| 2.7% | 2.7% | 1.7% | 1.2% | 1.6% | 1.7% | 2.2% | 1.5% | 1.6% | 3.2% | 1.3% | 2.0% | |
| 12.5% | 12.3% | 12.4% | 19.6% | 34.0% | 34.8% | 45.0% | 44.8% | 63.4% | 63.0% | 66.7% | 67.2% | |
| 58.7% | 60.7% | 61.0% | 56.8% | 44.9% | 44.7% | 38.0% | 35.8% | 8.6% | 8.1% | 10.1% | 11.5% | |
| -36.8% | -38.0% | -42.2% | -45.5% | -40.9% | -42.9% | -42.9% | -43.8% | -103.7% | -103.2% | -107.5% | -108.3% | |
| 11.0% | 11.6% | 11.9% | 11.5% | 9.6% | 9.7% | 8.9% | 8.7% | 12.6% | 11.8% | 13.0% | 12.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.